Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium
January 14 2021 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP),
(“Cocrystal” or the “Company”), a clinical-stage biotechnology
company discovering and developing novel antiviral therapeutics
that target the replication machinery of influenza viruses, the
SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces
that its President Sam Lee, Ph.D. will be making a presentation at
the virtual 3rd Annual reimagine Health Research Symposium,
University of Arizona College of Medicine, being held January 21,
2021.
During a presentation titled “Application of
structure-based drug design platform technology for developing
broad spectrum COVID-19, influenza, and HCV antivirals,” Dr. Lee
will discuss the use of the Company’s platform technology to
develop broad-spectrum antiviral inhibitors.
“We are delighted to have the opportunity to
present Cocrystal’s enabling technology as used for HCV, influenza
and COVID-19 drug discovery,” said Dr. Lee. “Last month we
announced the selection of a lead compound for further development
against coronaviruses, including SARS-CoV-2, as we advance our
COVID-19 program.”
About the reimagine Health Research
Symposium
The 3rd Annual reimagine Health Research
Symposium will focus on current topics in the areas of intervention
and prevention of important diseases that are impacting humankind.
It will emphasize approaches for a variety of diseases and
crises—including COVID-19, cardiovascular disease, cancer, opioid
addiction and the need to develop novel antibiotics. Attendees will
learn from and engage with leading experts who will present and
discuss contemporary treatment and prevention strategies in the
areas of drug discovery, vaccine development, addiction management
and the use of artificial intelligence, as well as the ethical and
social factors contributing to these approaches. The reimagine
Health Research Symposium is co-sponsored and planned by the
Arizona Biomedical Research Centre, the University of Arizona
College of Medicine – Phoenix Research Office and the Flinn
Foundation. More information about the symposium is available
here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024